Sagrelate Hydrochloride API

Name	Sagrelate Hydrochloride
Chinese name	盐酸沙格雷酯
Cas Number	135159-51-2
Source	India
Qualifications	-/-/-/-/-

Sagrelate Hydrochloride (trade name: Ambroxol) is a 5-HT2 receptor antagonist and platelet aggregation antagonist developed by Mitsubishi Tanabe Pharma in Japan. It was first listed in Japan in 1993 and in China in 2001. Ambrox is the second best-selling drug of Japan's Mitsubishi Pharmaceuticals, and a blockbuster product in the company's main drug treatment field-the cardiovascular system and the metabolic system. Sagrelate hydrochloride can selectively block 5-HT2 receptors, and at the same time has the effects of anti-platelet aggregation and inhibiting vasoconstriction. It has a unique effect on thromboembolic diseases such as chronic arterial occlusive disease. Clinical studies have shown that sagrelate hydrochloride can significantly improve the microcirculation, and can also promote the formation of collateral circulation, so it can improve the intermittent claudication, cold feeling and pain caused by thromboangiitis obliterans (TAO) , Ulcers and other ischemic symptoms and signs. In addition, sargresil hydrochloride also has obvious antithrombotic effects. This product is recommended for the treatment of peripheral vascular disease (PAD) guidelines.

Hot Tags: sagrelate hydrochloride api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Lercanidipine Hydrochloride API, Aprepitant Aprepitant API, Tippyridine Hydrochloride API, Bosentan API, Bemeprost API, Active Pharmaceutical Ingredient

• Previous: Varenicline Tartrate API
• Next: Glucosamine Sulfate Sodium Chloride Double Salt API